Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -547.6%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $20M | $12M | $17M | $40M | $113M | $1.2B | $342M |
| Enterprise Value | $17M | $9M | $16M | $38M | $113M | $1.2B | $341M |
| P/E Ratio → | -0.70 | — | — | — | — | — | 828.57 |
| P/S Ratio | 17.49 | 10.40 | 160.64 | 80.12 | — | 36522.88 | 24.62 |
| P/B Ratio | 2.26 | 1.56 | — | 366.06 | — | — | 212.20 |
| P/FCF | — | — | — | — | — | — | 954.38 |
| P/OCF | — | — | — | — | — | — | 808.85 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.00 | 150.30 | 75.82 | — | 36558.35 | 24.53 |
| EV / EBITDA | — | — | — | — | — | — | 804.40 |
| EV / EBIT | — | — | — | — | — | — | 824.89 |
| EV / FCF | — | — | — | — | — | — | 950.58 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 56.5% | 56.5% | 38.0% | 100.0% | — | 100.0% | 15.9% |
| Operating Margin | -753.5% | -753.5% | -8500.0% | -618.1% | — | -14543.8% | 3.0% |
| Net Profit Margin | -1741.0% | -1741.0% | -9685.2% | -522.7% | — | -13690.6% | 3.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -547.6% | -547.6% | — | -2388.1% | — | — | 25.6% |
| ROA | -263.7% | -263.7% | -288.9% | -187.5% | -696.5% | -185.4% | 11.0% |
| ROIC | -379.7% | -379.7% | — | — | — | — | — |
| ROCE | -236.3% | -236.3% | — | -2823.9% | — | — | 20.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.31 |
| Debt / EBITDA | — | — | — | — | — | — | 1.17 |
| Net Debt / Equity | — | -0.36 | — | -19.66 | — | — | -0.84 |
| Net Debt / EBITDA | — | — | — | — | — | — | -3.21 |
| Debt / FCF | — | — | — | — | — | — | -3.80 |
| Interest Coverage | -124.01 | -124.01 | -150.57 | -143.56 | -5.60 | -31.45 | — |
Net cash position: cash ($3M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | 1.43 | 0.53 | 0.89 | 0.04 | 0.18 | 1.86 |
| Quick Ratio | 1.39 | 1.39 | 0.53 | 0.89 | 0.04 | 0.18 | 1.86 |
| Cash Ratio | 0.97 | 0.97 | 0.36 | 0.85 | 0.03 | 0.16 | 1.03 |
| Asset Turnover | — | 0.11 | 0.02 | 0.19 | — | 0.03 | 3.68 |
| Inventory Turnover | 4.60 | 4.60 | — | — | — | — | — |
| Days Sales Outstanding | — | 62.01 | 408.94 | 61.57 | — | 467.66 | 37.86 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.1% |
| FCF Yield | — | — | — | — | — | — | 0.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $13M | $7M | $8M | $8M | $8M | $8M |
Critical liquidity runway depletion
Based on reported figures, AIFF trades at a price-to-sales multiple of 18.00, a valuation that appears to price in significant future growth expectations despite the company's current lack of profitability and the inherent lumpiness of its project-based revenue streams compared to established software peers.
The 18.00x P/S ratio suggests that investors are valuing the firm as a high-growth technology play rather than a traditional medical device manufacturer. This multiple warrants caution, as it implies a rapid scaling of recurring revenue that has yet to be demonstrated in the quarterly financial history.
As reported in financial statements, the company's net margin of -1740.98% and operating margin of -753.50% underscore a business model currently prioritizing R&D and market entry over immediate profitability, with gross margins fluctuating significantly due to the variable nature of its current service-heavy revenue mix.
The extreme negative margins suggest that the current revenue base is insufficient to absorb the fixed costs of specialized neuroscientific talent and public company compliance. Investors should monitor whether gross margins stabilize as the company potentially shifts toward a more scalable, software-centric delivery model.
According to recent quarterly data, the company's cash conversion cycle remains deeply negative, with days sales outstanding reaching as high as 3,261 days in 2024Q1, reflecting significant challenges in converting project-based contract milestones into timely cash inflows compared to standard industry benchmarks.
The erratic nature of the CCC suggests that the firm lacks leverage over its customer base, leading to extended collection periods that exacerbate liquidity pressures. This inefficiency appears structural, likely stemming from the long-duration nature of pharmaceutical clinical trial contracts.
Based on the most recent quarterly filings, the current ratio of 1.82 provides a superficial sense of stability, yet the absolute cash balance of $2.7 million against persistent quarterly cash burn suggests a vulnerable liquidity position that may necessitate dilutive financing in the near term.
While the current ratio appears adequate on paper, the lack of consistent operating cash flow means the company is highly dependent on external capital to fund its ongoing operations. This reliance on external funding sources creates a binary risk profile for shareholders should capital market conditions tighten.
The most commonly misapplied metric for AIFF is the price-to-earnings ratio, which is fundamentally misleading for a pre-revenue or early-commercial stage firm where earnings are non-existent and distorted by heavy R&D investment and stock-based compensation.
Investors should instead focus on the growth of active BNA licenses and the pharmaceutical contract backlog as more reliable indicators of future value. Relying on P/E or standard profitability ratios obscures the company's true progress in establishing its proprietary database as a clinical standard.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AIFF stock.
Firefly Neuroscience, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
Firefly Neuroscience, Inc.'s return on equity (ROE) is -547.6%. The historical average is 25.6%.
Based on historical data, Firefly Neuroscience, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Firefly Neuroscience, Inc. has 56.5% gross margin and -753.5% operating margin.